GNLX Genelux Corporation
USHealthcareAs of 2026-07-10 16:00
Why GNLX matters now
Genelux Corporation (GNLX) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.03 with +1.68% on the session and $114.0M in market capitalization; recent performance reads 1-month +5.89% and YTD -32.00%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-7.1M, and EPS of $-0.22. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -25.0%.
The latest indexable market news headline is "Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $16.00; recent insider activity includes Smither John W filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.20
P/S
13941.77
EV/EBITDA
-3.27
DCF Value
$-0.01
FCF Yield
-25.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-3550.0%
Operating Margin
-422037.5%
Net Margin
-397225.0%
ROE
-165.2%
ROA
-98.2%
ROIC
-132.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-7.1M | $-0.22 |
| Q4 2025 | $8.0K | $-9.2M | $-0.25 |
| FY 2025 | $8.0K | $-32.1M | $-0.86 |
| Q3 2025 | $0.00 | $-8.0M | $-0.21 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$17.33
Target (Median)
$16.00
Target Range
$16.00 - $20.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.55
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.